Presentasjon om India

DiaGenic presenterer ”India – A market of opportunities” torsdag 5. juni kl. 10:30 -12:00.

10:30 Velkommen
Håkon Sæterøy, Executive Chairman DiaGenic

10:35 Utviklingen av brystkrefttesten
Derek Tobin, PhD, Project Manager DiaGenic

10:55 DiaGenic i India; mulighetenes marked
Avi Chaudhuri, PhD, PAC Med Biotech Pvt. Ltd.

11:45 Valget av en kommersiell partner; SRL Ranbaxy LTD
MD PhD Erik Christensen, CEO DiaGenic

Presentasjonen vil bli sendt i sanntid og være tilgjengelig via webcast og telefon. Webcast og telefonkonferansen vil også være tilgjengelig på våre hjemmesider: i etterkant av presentasjonen.

Link til webcast:

Telefonkonferanse detaljer: Se vedlegg

Presentasjoner følger vedlagt

Om oss

DiaGenic ASA is an innovative Norwegian life sciences company founded in 1998 and listed on the Oslo Stock Exchange. DiaGenic develops patient-friendly tests for the early diagnosis of devastating diseases where early intervention is crucial for successful treatment. DiaGenic’s patented method is based on identifying disease-specific gene signatures from easily available sample material such as blood. DiaGenic's strategy is to work with research and technology partners to develop a pipeline of assays for commercialisation by major diagnostics companies. Currently DiaGenic’s first two tests for the early detection of breast cancer and Alzheimer’s disease are on track to enter extensive clinical trials during 2007. The company has been awarded substantial development grants as part of the Norwegian Research Council’s FUGE programme.